These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34514554)

  • 1. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
    Van J; Frias JP; Bonora E; Raha S; Meyer J; Jung H; Cox D; Konig M; Peleshok J; Bethel MA
    Diabetes Ther; 2021 Oct; 12(10):2783-2794. PubMed ID: 34514554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
    Guo L; Zhang B; Hou J; Zhou Z
    Diabetes Ther; 2020 Aug; 11(8):1821-1833. PubMed ID: 32621083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
    Kuang J; Zhu J; Liu S; Li Q
    Diabetes Ther; 2020 Oct; 11(10):2329-2339. PubMed ID: 32857293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
    Lingvay I; Hansen T; Macura S; Marre M; Nauck MA; de la Rosa R; Woo V; Yildirim E; Wilding J
    BMJ Open Diabetes Res Care; 2020 Oct; 8(2):. PubMed ID: 33115821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
    Trujillo J
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.
    Kugler AJ; Thiman ML
    Diabetes Metab Syndr Obes; 2018; 11():187-197. PubMed ID: 29780260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
    Li YM; Zhang LH; Li XJ; Zhang B; Hou JN; Tong NW
    Diabetes Ther; 2020 May; 11(5):1077-1090. PubMed ID: 32219675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
    Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
    Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Yu K; Quan X; Yang Z; Wu S; Zhang Y; Ji L; Wang J; Shi L
    Diabetes Technol Ther; 2015 Jan; 17(1):35-42. PubMed ID: 25375397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
    Gurung T; Shyangdan DS; O'Hare JP; Waugh N
    Diabetes Metab Syndr Obes; 2015; 8():363-86. PubMed ID: 26316788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal safety across the albiglutide development programme.
    Leiter LA; Mallory JM; Wilson TH; Reinhardt RR
    Diabetes Obes Metab; 2016 Sep; 18(9):930-5. PubMed ID: 27097971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
    Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
    Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.